Due to the quiescent nature of CLL cells in peripheral blood, we focused our studies of TG02 on inhibition of CDK9 and transcription, rather than the CDKs that regulate cell cycle progression. This evidence concerns the gene CDK9 and B-cell chronic lymphocytic leukemia.